Fresenius Medical Care Corporation (FMS) Given Consensus Rating of “Hold” by Brokerages

Fresenius Medical Care Corporation (NYSE:FMS) has received an average recommendation of “Hold” from the thirteen ratings firms that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, five have given a hold rating and seven have given a buy rating to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $46.00.

Several equities analysts have recently weighed in on the company. Nord/LB restated a “buy” rating on shares of Fresenius Medical Care Corporation in a report on Wednesday, June 28th. Royal Bank Of Canada restated a “hold” rating and issued a $44.00 price objective on shares of Fresenius Medical Care Corporation in a report on Wednesday, July 5th. UBS AG restated a “sell” rating on shares of Fresenius Medical Care Corporation in a report on Tuesday, July 4th. Zacks Investment Research upgraded Fresenius Medical Care Corporation from a “hold” rating to a “buy” rating and set a $54.00 price objective for the company in a report on Tuesday, July 11th. Finally, BidaskClub cut Fresenius Medical Care Corporation from a “strong-buy” rating to a “buy” rating in a report on Monday, July 24th.

Shares of Fresenius Medical Care Corporation (FMS) traded up 0.66% during mid-day trading on Tuesday, hitting $48.63. The company’s stock had a trading volume of 438,134 shares. Fresenius Medical Care Corporation has a 1-year low of $38.05 and a 1-year high of $50.22. The stock has a market cap of $29.85 billion, a PE ratio of 21.41 and a beta of 0.48. The company has a 50-day moving average price of $46.81 and a 200-day moving average price of $45.69.

Fresenius Medical Care Corporation (NYSE:FMS) last announced its quarterly earnings data on Tuesday, August 1st. The company reported $0.48 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.53 by ($0.05). The company had revenue of $4.47 billion during the quarter, compared to the consensus estimate of $5.20 billion. Fresenius Medical Care Corporation had a net margin of 7.06% and a return on equity of 11.57%. Fresenius Medical Care Corporation’s revenue was up 11.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.96 EPS. Analysts predict that Fresenius Medical Care Corporation will post $2.35 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was first posted by Stock Observer and is owned by of Stock Observer. If you are accessing this report on another website, it was stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this report can be accessed at https://www.thestockobserver.com/2017/09/12/fresenius-medical-care-corporation-fms-given-consensus-rating-of-hold-by-brokerages.html.

A number of large investors have recently modified their holdings of the stock. Harding Loevner LP lifted its stake in Fresenius Medical Care Corporation by 6.2% in the 2nd quarter. Harding Loevner LP now owns 3,748,173 shares of the company’s stock valued at $181,149,000 after purchasing an additional 219,213 shares during the last quarter. Cambiar Investors LLC lifted its stake in Fresenius Medical Care Corporation by 3.2% in the 2nd quarter. Cambiar Investors LLC now owns 2,596,480 shares of the company’s stock valued at $125,488,000 after purchasing an additional 80,064 shares during the last quarter. Bank of America Corp DE lifted its stake in Fresenius Medical Care Corporation by 12.1% in the 1st quarter. Bank of America Corp DE now owns 1,493,411 shares of the company’s stock valued at $62,917,000 after purchasing an additional 161,262 shares during the last quarter. Royal Bank of Canada lifted its stake in Fresenius Medical Care Corporation by 6.4% in the 2nd quarter. Royal Bank of Canada now owns 501,694 shares of the company’s stock valued at $24,248,000 after purchasing an additional 30,119 shares during the last quarter. Finally, US Bancorp DE lifted its stake in Fresenius Medical Care Corporation by 10.4% in the 2nd quarter. US Bancorp DE now owns 427,021 shares of the company’s stock valued at $20,637,000 after purchasing an additional 40,121 shares during the last quarter. Institutional investors and hedge funds own 2.61% of the company’s stock.

Fresenius Medical Care Corporation Company Profile

Fresenius Medical Care AG & Co KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company’s segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment.

Analyst Recommendations for Fresenius Medical Care Corporation (NYSE:FMS)

Receive News & Ratings for Fresenius Medical Care Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply